Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Telmisartan 80mg: Telmisartan 80mg once daily for 8 weeks
Control Intervention1: Telmisartan 40mg + Amlodipine 5mg: Telmisartan 40mg + Amlodipine 5mg once daily for 8 weeks
Sponsors
Dr Spandana
Eligibility
Inclusion criteria
Inclusion criteria: Patients willing to give informed consent and willing to follow up Patients having uncontrolled blood pressure more than 140mmHg systolic and more than 90mmHg diastolic blood pressure as per JNC guidelines who are on low dose monotherapy with Telmisartan for atleast 4 weeks
Exclusion criteria
Exclusion criteria: Patients having comorbidities like chronic kidney disease, stroke congestive heart failure coronary heart disease psychiatric disorders suspected secondary hypertension liver disease malignancy Pregnant and lactating mothers Patients with hypersensitivity to the study medications Psychiatric or emotional disturbance in patients which would limit ability of patients to comply The patient with increased levels of potassium The patient with hypertensive complications like retinopathy Cardiovascular disease nephropathy peripheral vascular disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy parameters Efficacy endpoints- reduction in systolic blood pressure by more than or equal to 15mmHg and diastolic blood pressure by more than or equal to 10mmHg from baseline Patients achieving target blood pressure of less than or equal to 140mmg systolic and 90mmHg diastolic blood pressureTimepoint: Baseline 4 weeks and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety parameters Safety is assessed by monitoring and recording adverse events reported by the patient at any time of the studyTimepoint: 4 weeks and 8 weeks | — |
Countries
India
Contacts
Public ContactDr Spandana
Bangalore medical college and research centre
Outcome results
None listed